Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 9/20 | 0.51 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.51 |
| ▸ | ABHD6 | Q9BV23 | 4/20 | 0.49 |
| ▸ | DAGLA | Q9Y4D2 | 4/20 | 0.49 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6986716 | 0.86 | FABP4 (0.44) | HCRTR1HCRTR2ABHD6DAGLA | |
| SCHEMBL6989529 | 0.84 | NAMPT (0.50) | HCRTR1HCRTR2ABHD6DAGLANAMPT | |
| SCHEMBL3703636 | 0.82 | RAB9A (0.48) | KMT2A | |
| SCHEMBL3703633 | 0.82 | RAB9A (0.48) | KMT2A | |
| SCHEMBL6989168 | 0.81 | DAGLA (0.48) | HCRTR1HCRTR2ABHD6DAGLANAMPT | |
| SCHEMBL3692443 | 0.80 | FABP4 (0.43) | HCRTR1HCRTR2ABHD6DAGLA | |
| SCHEMBL6987416 | 0.78 | FABP4 (0.43) | HCRTR1HCRTR2NAMPT | |
| SCHEMBL6988101 | 0.77 | FABP4 (0.50) | HCRTR1HCRTR2NAMPT | |
| SCHEMBL2258523 | 0.77 | ABHD6 (0.54) | HCRTR1HCRTR2ABHD6DAGLAKMT2A | |
| SCHEMBL6989539 | 0.77 | SCD5 (0.55) | HCRTR1HCRTR2ABHD6DAGLANAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889683-B2 | Substituted quinoxalines as inhibitors of fatty acid binding protein | MERCK SHARP & DOHME CORP. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889683-B2 | Substituted quinoxalines as inhibitors of fatty acid binding protein | MERCK SHARP & DOHME CORP. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20120122837-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN | MERCK SHARP & DOHME LLC | 2012-05-17 | — | — | US | disclosed |
| US-20120122837-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN | MERCK SHARP & DOHME LLC | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122837-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN | FABP4, FABP1, FABP3 | HCRTR1 4346/4885HCRTR2 3592/4885ABHD6 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.